The Centers for Medicare & Medicaid Services unveiled the next cohort of 15 high-spend medicines selected for price negotiations under the Inflation Reduction Act. CMS named brands across multiple therapeutic areas — from Eli Lilly’s Trulicity to AbbVie’s Botox and Roche/Novartis biologics — and said negotiated prices will take effect in early 2028. CMS reported the group accounted for roughly $27 billion in Medicare Part B and D spending from November 2024–October 2025 and touched about 1.8 million beneficiaries. The list includes first-time Part B medicines to face IRA-enabled cuts, widening the program’s reach beyond pharmacy-dispensed drugs. Manufacturers have until the end of February to decide whether to participate; the announcement ramps up the commercial and pricing stakes for major immunology, oncology, diabetes and specialty biologic franchises. CMS described the selection as part of its ongoing implementation of IRA authorities and noted renegotiations for previously included medicines where applicable. Industry participants will now weigh negotiation strategies, potential legal challenges, and forecasting impacts on revenue, market access, and contracting ahead of the statutory timeline.